116 related articles for article (PubMed ID: 8626880)
1. Diurnal variation in the pharmacokinetics of nizatidine in healthy volunteers and in patients with peptic ulcer disease.
Jamali F; Thomson AB; Kirdeikis P; Tavernini M; Zuk L; Marriage B; Simpson I; Mahachai V
J Clin Pharmacol; 1995 Nov; 35(11):1071-5. PubMed ID: 8626880
[TBL] [Abstract][Full Text] [Related]
2. Twice daily nizatidine or ranitidine is superior to once daily dosing in elevating 24 h intragastric pH in patients with duodenal ulcer disease.
Thomson AB; Mahachai V; Bailey RJ; Kirdeikis P; Zuk L; Marriage B; Simpson I; Jamali F
J Gastroenterol Hepatol; 1996 Dec; 11(12):1171-6. PubMed ID: 9034938
[TBL] [Abstract][Full Text] [Related]
3. Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
Savarino V; Mela GS; Zentilin P; Cutela P; Mele R; Celle G
J Clin Pharmacol; 1993 Jan; 33(1):70-4. PubMed ID: 8429117
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects.
Blum RA; Braverman AJ; Rice P; Johnson FK
J Clin Pharmacol; 2003 Jan; 43(1):74-83. PubMed ID: 12520631
[TBL] [Abstract][Full Text] [Related]
5. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
Price AH; Brogden RN
Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
[TBL] [Abstract][Full Text] [Related]
7. Effect of nizatidine and ranitidine on 24 hour intragastric pH, pepsin, prostaglandin E2 and serum gastrin concentrations in healthy volunteers.
Thompson A; Kirdeikis P; Jamali F; Tavernini M; Zuk L; Marriage B; Simpson I; Mahachai V
J Gastroenterol Hepatol; 1995; 10(5):546-54. PubMed ID: 8963030
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ranitidine and nizatidine in very elderly patients.
Sasaki M; Sudoh T; Fujimura A
Am J Ther; 2005; 12(3):223-5. PubMed ID: 15891265
[TBL] [Abstract][Full Text] [Related]
9. [Inhibition of 24-hour acidity by nizatidine].
Dammann HG; Dreyer M; Gottlieb WR; Wolf N; Müller P; Simon B
Fortschr Med; 1989 May; 107(14):321-4. PubMed ID: 2568971
[TBL] [Abstract][Full Text] [Related]
10. [Nizatidine].
Romero M; Franzosi MG
Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
[TBL] [Abstract][Full Text] [Related]
11. Healing and recurrence of active duodenal ulcer with nizatidine.
Cloud ML; Offen WW; Matsumoto C; Chernish SM
Clin Pharmacol Ther; 1989 Sep; 46(3):310-6. PubMed ID: 2570656
[TBL] [Abstract][Full Text] [Related]
12. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
Lima M; Holdcroft C
Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
[TBL] [Abstract][Full Text] [Related]
13. Comparison of nizatidine and cimetidine as once-nightly treatment of acute duodenal ulcer. Nizatidine Multicenter Duodenal Ulcer Study Group.
Cherner JA; Cloud ML; Offen WW; Latz JE
Am J Gastroenterol; 1989 Jul; 84(7):769-74. PubMed ID: 2568086
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers.
Lockyer M; Al-Dgither S; Al-Gaai E; Yousuf A; Hammami MM
Biopharm Drug Dispos; 2005 Apr; 26(3):117-20. PubMed ID: 15723428
[TBL] [Abstract][Full Text] [Related]
15. Nizatidine as maintenance therapy of duodenal ulcer disease in remission.
Cerulli MA; Cloud ML; Offen WW; Chernish SM; Matsumoto C
Scand J Gastroenterol Suppl; 1987; 136():79-83. PubMed ID: 2892259
[TBL] [Abstract][Full Text] [Related]
16. Treatment of duodenal ulceration in the United States.
Dyck WP; Cloud ML; Offen WW; Matsumoto C; Chernish SM
Scand J Gastroenterol Suppl; 1987; 136():47-55. PubMed ID: 2892255
[TBL] [Abstract][Full Text] [Related]
17. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
[TBL] [Abstract][Full Text] [Related]
19. Nizatidine versus placebo in active benign gastric ulcer disease: an eight-week, multicenter, randomized, double-blind comparison. The Nizatidine Benign Gastric Ulcer Disease Study Group.
Cloud ML; Enas N; Offen WW
Clin Pharmacol Ther; 1992 Sep; 52(3):307-13. PubMed ID: 1526089
[TBL] [Abstract][Full Text] [Related]
20. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
Levendoglu H; Mehta B; Wait C; Reddy G; Hatcher C
Am J Gastroenterol; 1986 Dec; 81(12):1167-70. PubMed ID: 2878607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
